Rumor: Sarepta Therapeutics Chairman Moves To Keep CEO Out Of FDA Meetings

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

The board of Sarepta Therapeutics has taken actions to limit CEO Chris Garabedian’s role at the company and to keep him from attending meetings with the FDA, The Wall Street Journal cites anonymous sources as saying.

The WSJ said that two people familiar with the matter told the paper that Sarepta (Nasdaq: SRPT) Chairman William Goolsbee told the executive team in July, at a meeting that Garabedian attended, that he “would no longer attend ... meetings with the FDA.” The sources also reportedly said that Garabedian would no longer have a “final say in decisions about clinical trial design and patient safety.”

Help employers find you! Check out all the jobs and post your resume.

Back to news